BACKGROUND:Generalized anxiety disorder (GAD) and major depressive disorder (MDD) are highly comorbid. A possible explanation is that they share four symptoms according to the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR). The present study addressed the symptom overlap of people meeting DSM-IV-TR diagnostic criteria for GAD, MDD, or both to investigate whether comorbidity might be explained by overlapping diagnostic criteria. METHODS:Participants (N = 1,218) were enrolled in the Coordinated Anxiety Learning and Management study (a randomized effectiveness clinical trial in primary care). Hypotheses were (1) the comorbid GAD/MDD group endorses the overlapping symptoms more than the nonoverlapping symptoms, and (2) the comorbid GAD/MDD group endorses the overlapping symptoms more than GAD only or MDD only groups, whereas differences would not occur for nonoverlapping symptoms. RESULTS: The overlapping GAD/MDD symptoms were endorsed more by the comorbid group than the MDD group but not the GAD group when covarying for total symptom endorsement. Similarly, the comorbid group endorsed the overlapping symptoms more than the nonoverlapping symptoms and did not endorse the nonoverlapping symptoms more than the GAD or MDD groups when covarying for total symptom endorsement. CONCLUSIONS: The results suggest that comorbidity of GAD and MDD is strongly influenced by diagnostic overlap. Results are discussed in terms of errors of diagnostic criteria, as well as models of shared psychopathology that account for diagnostic criteria overlap.
RCT Entities:
BACKGROUND:Generalized anxiety disorder (GAD) and major depressive disorder (MDD) are highly comorbid. A possible explanation is that they share four symptoms according to the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR). The present study addressed the symptom overlap of people meeting DSM-IV-TR diagnostic criteria for GAD, MDD, or both to investigate whether comorbidity might be explained by overlapping diagnostic criteria. METHODS:Participants (N = 1,218) were enrolled in the Coordinated Anxiety Learning and Management study (a randomized effectiveness clinical trial in primary care). Hypotheses were (1) the comorbid GAD/MDD group endorses the overlapping symptoms more than the nonoverlapping symptoms, and (2) the comorbid GAD/MDD group endorses the overlapping symptoms more than GAD only or MDD only groups, whereas differences would not occur for nonoverlapping symptoms. RESULTS: The overlapping GAD/MDD symptoms were endorsed more by the comorbid group than the MDD group but not the GAD group when covarying for total symptom endorsement. Similarly, the comorbid group endorsed the overlapping symptoms more than the nonoverlapping symptoms and did not endorse the nonoverlapping symptoms more than the GAD or MDD groups when covarying for total symptom endorsement. CONCLUSIONS: The results suggest that comorbidity of GAD and MDD is strongly influenced by diagnostic overlap. Results are discussed in terms of errors of diagnostic criteria, as well as models of shared psychopathology that account for diagnostic criteria overlap.
Authors: Peter Roy-Byrne; Michelle G Craske; Greer Sullivan; Raphael D Rose; Mark J Edlund; Ariel J Lang; Alexander Bystritsky; Stacy Shaw Welch; Denise A Chavira; Daniela Golinelli; Laura Campbell-Sills; Cathy D Sherbourne; Murray B Stein Journal: JAMA Date: 2010-05-19 Impact factor: 56.272
Authors: Raphael D Rose; Ariel J Lang; Stacy Shaw Welch; Laura Campbell-Sills; Denise A Chavira; Greer Sullivan; Cathy Sherbourne; Alexander Bystritsky; Murray B Stein; Peter P Roy-Byrne; Michelle G Craske Journal: Gen Hosp Psychiatry Date: 2011-06-08 Impact factor: 3.238
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Karen S Mitchell; Erika J Wolf; Michelle J Bovin; Lewina O Lee; Jonathan D Green; Raymond C Rosen; Terence M Keane; Brian P Marx Journal: J Abnorm Psychol Date: 2017-02-13
Authors: Lisa R Steenkamp; Christina M Hough; Victor I Reus; Felipe A Jain; Elissa S Epel; S Jill James; Alexandra E Morford; Synthia H Mellon; Owen M Wolkowitz; Daniel Lindqvist Journal: J Affect Disord Date: 2017-05-06 Impact factor: 4.839
Authors: Catherine S John; Elizabeth I Sypek; William A Carlezon; Bruce M Cohen; Dost Öngür; Anita J Bechtholt Journal: Neuropsychopharmacology Date: 2015-01-14 Impact factor: 7.853
Authors: C Beard; A J Millner; M J C Forgeard; E I Fried; K J Hsu; M T Treadway; C V Leonard; S J Kertz; T Björgvinsson Journal: Psychol Med Date: 2016-09-14 Impact factor: 7.723
Authors: Jessica Bomyea; Ariel Lang; Michelle G Craske; Denise A Chavira; Cathy D Sherbourne; Raphael D Rose; Daniela Golinelli; Laura Campbell-Sills; Stacy S Welch; Greer Sullivan; Alexander Bystritsky; Peter Roy-Byrne; Murray B Stein Journal: Psychiatry Res Date: 2015-07-21 Impact factor: 3.222